The collaboration will focus on evaluating MCHC’s closed hydroponic cultivation system, plant factory system, developed to grow plants.
Medicago’s technologies will be used to produce Nicotiana Benthamiana plants for protein production.
Medicago president and chief executive officer Andy Sheldon said, "This system would be designed to enhance our capacity and further decrease operating costs, whilst facilitating new applications of Medicago’s technology."
According to the deal, the companies will jointly work for a year to integrate MCHC’s plant factory system with Medicago’s plant protein production technologies.
MCHC’s Plant Factory System that utilizes solar panels and LED lighting is designed to provide efficient, clean, safe, environmentally friendly and reliable biopharmaceutical plant production.
MCHC healthcare solutions office head executive officer Dr. Seiichi Kiso said, "Medicago and Mitsubishi have both developed very promising technologies and we see a significant opportunity from joining the two technologies into a next generation plant protein production platform."